Literature DB >> 8166661

Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.

L Tessitore1, P Costelli, F M Baccino.   

Abstract

Marked loss of body weight and profound waste of both skeletal muscle and white adipose tissue occur in rats into which the ascites hepatoma Yoshida AH-130 has been transplanted, associated with marked perturbations in the hormonal homoeostasis and the presence of circulating tumour necrosis factor and high plasma levels of prostaglandin E2 [Tessitore, Costelli and Baccino (1993) Br. J. Cancer 67, 15-23]. On the basis of previous findings, the present study examined whether the development of cachexia in this model system could be significantly affected by adrenalectomy or by pharmacological treatments that may interfere with proximal or distal mediators of tissue hypercatabolism. In no instance was tumour growth modified. Medroxyprogesterone acetate, an anabolic-hormone-like drug, was completely ineffective. In adrenalectomized animals, although changes such as the elevation of plasma triacylglycerols and corticosterone were corrected, the general course of cachexia was not modified. A partial prevention of muscle waste was observed with acetylsalicylic acid, a non-steroidal anti-inflammatory drug, or with leupeptin, a proteinase inhibitor. Insulin afforded the most significant preservation of muscle protein and adipose-tissue mass, which were maintained close to control values even 10 days after transplantation. The effects of insulin on gastrocnemius muscle and liver protein content were exerted by slowing down protein turnover, mainly enhancing synthesis. Consistently, the total free amino acid concentration in the gastrocnemius of insulin-treated rats 10 days after tumour transplantation was close to that of controls. Although treatment with insulin decreased plasma corticosterone to normal values, it did not modify the circulating level of tumour necrosis factor. On the whole these data show that it seems possible to prevent, at least in part, the tissue waste that characterizes cancer cachexia by purely pharmacological means.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166661      PMCID: PMC1138022          DOI: 10.1042/bj2990071

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  56 in total

1.  Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer.

Authors:  P L Baron; W Lawrence; W M Chan; F K White; W L Banks
Journal:  Arch Surg       Date:  1986-11

2.  Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia.

Authors:  F Bozzetti; M Ammatuna; S Migliavacca; M G Bonalumi; G Facchetti; A Pupa; G Terno
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

3.  Tumor-host wasting not explained by adrenal hyperfunction in tumor-bearing animals.

Authors:  G Svaninger; J Gelin; K Lundholm
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

4.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

Authors:  I C Kettelhut; W Fiers; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  Altered leucine metabolism in noncachectic sarcoma patients.

Authors:  R I Inculet; T P Stein; J L Peacock; M Leskiw; M Maher; C M Gorschboth; J A Norton
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

6.  Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting.

Authors:  G Svaninger; C Drott; K Lundholm
Journal:  J Natl Cancer Inst       Date:  1987-05       Impact factor: 13.506

7.  Impact of insulin on doxorubicin-induced rat host toxicity and tumor regression.

Authors:  J L Peacock; C M Gorschboth; J A Norton
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

8.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.

Authors:  P Costelli; N Carbó; L Tessitore; G J Bagby; F J Lopez-Soriano; J M Argilés; F M Baccino
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia.

Authors:  L Tessitore; G Bonelli; F M Baccino
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

10.  Whole-body protein kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion and total parenteral nutrition.

Authors:  J H Shaw; R R Wolfe
Journal:  Surgery       Date:  1988-02       Impact factor: 3.982

View more
  13 in total

1.  Antitumour activity of crocetin in accordance to tumor incidence, antioxidant status, drug metabolizing enzymes and histopathological studies.

Authors:  Venkatraman Magesh; Jayapal Prince Vijaya Singh; Karupaya Selvendiran; Ganapathy Ekambaram; Dhanapal Sakthisekaran
Journal:  Mol Cell Biochem       Date:  2006-05-10       Impact factor: 3.396

Review 2.  Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.

Authors:  Megan E Rosa-Caldwell; Dennis K Fix; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2019-11-14

3.  Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.

Authors:  Theodore P Braun; Aaron J Grossberg; Stephanie M Krasnow; Peter R Levasseur; Marek Szumowski; Xin Xia Zhu; Julia E Maxson; J Gabriel Knoll; Anthony P Barnes; Daniel L Marks
Journal:  FASEB J       Date:  2013-06-03       Impact factor: 5.191

4.  Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.

Authors:  P Costelli; C García-Martínez; M Llovera; N Carbó; F J López-Soriano; N Agell; L Tessitore; F M Baccino; J M Argilés
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

5.  Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.

Authors:  Kunihiro Sakuma; Akihiko Yamaguchi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-01-12       Impact factor: 12.910

6.  Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis.

Authors:  Theodore P Braun; Xinxia Zhu; Marek Szumowski; Gregory D Scott; Aaron J Grossberg; Peter R Levasseur; Kathryn Graham; Sheehan Khan; Sambasivarao Damaraju; William F Colmers; Vickie E Baracos; Daniel L Marks
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

7.  Induction of muscle protein degradation by a tumour factor.

Authors:  M J Lorite; P Cariuk; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats.

Authors:  N Carbó; J López-Soriano; P Costelli; S Busquets; B Alvarez; F M Baccino; L S Quinn; F J López-Soriano; J M Argilés
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 9.  The regulation of muscle mass by endogenous glucocorticoids.

Authors:  Theodore P Braun; Daniel L Marks
Journal:  Front Physiol       Date:  2015-02-03       Impact factor: 4.566

10.  Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.

Authors:  Agnès Martin; Josiane Castells; Valentine Allibert; Andréa Emerit; Cindy Zolotoff; Victoire Cardot-Ruffino; Yann S Gallot; Barbara Vernus; Véronique Chauvet; Laurent Bartholin; Laurent Schaeffer; Anne-Cécile Durieux; Christophe Hourdé; François B Favier; Laetitia Mazelin; Damien Freyssenet
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-11       Impact factor: 12.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.